KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesDividends payablesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Eli Lilly (LLY) Inventory (2016 - 2025)

Historic Inventory for Eli Lilly (LLY) over the last 17 years, with Q3 2025 value amounting to $12.2 billion.

  • Eli Lilly's Inventory rose 6328.05% to $12.2 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $12.2 billion, marking a year-over-year increase of 6328.05%. This contributed to the annual value of $7.6 billion for FY2024, which is 3146.48% up from last year.
  • As of Q3 2025, Eli Lilly's Inventory stood at $12.2 billion, which was up 6328.05% from $11.0 billion recorded in Q2 2025.
  • Eli Lilly's 5-year Inventory high stood at $12.2 billion for Q3 2025, and its period low was $3.7 billion during Q1 2021.
  • In the last 5 years, Eli Lilly's Inventory had a median value of $4.8 billion in 2023 and averaged $5.9 billion.
  • Its Inventory has fluctuated over the past 5 years, first tumbled by 236.92% in 2021, then skyrocketed by 6992.67% in 2025.
  • Eli Lilly's Inventory (Quarter) stood at $3.9 billion in 2021, then grew by 10.9% to $4.3 billion in 2022, then skyrocketed by 33.95% to $5.8 billion in 2023, then skyrocketed by 31.46% to $7.6 billion in 2024, then skyrocketed by 60.5% to $12.2 billion in 2025.
  • Its Inventory was $12.2 billion in Q3 2025, compared to $11.0 billion in Q2 2025 and $9.3 billion in Q1 2025.